Abstract RAS proteins control cell proliferation and activating mutations are collectively the most frequent oncogenic event observed in cancer patients, justifying investments into multiple drug discovery efforts. While RAS-directed therapeutic agents targeting either the inactive GDP-bound or the active GTP-bound state have entered the clinic, invariably resistance is observed.
Get in touch with Kim
Contact Kim, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack